Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NR4A1 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 4immunitygroup A member 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR4A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR2E3 Biologics Sequence Review Report 2026: Photoreceptor-specific nuclear receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR2E3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR2C2 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 2 group C member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR2C2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR2C1 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 2 group C member 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR2C1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR1I2 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 1 group I member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR1I2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR1H4 Biologics Sequence Review Report 2026: Bile acid receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR1H4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR1H3 Biologics Sequence Review Report 2026: Oxysterols receptor LXR-alpha Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR1H3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR1H2 Biologics Sequence Review Report 2026: Oxysterols receptor LXR-beta Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR1H2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NR1D2 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 1 group D member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NR1D2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NPFFR2 Biologics Sequence Review Report 2026: Neuropeptide FF receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NPFFR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NPFFR1 Biologics Sequence Review Report 2026: Neuropeptide FF receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NPFFR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NOS1AP Biologics Sequence Review Report 2026: Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of NOS1AP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.